Negative inotropic effects of diadenosine tetraphosphate are mediated by protein kinase C and phosphodiesterases stimulation in the rat heart

[1]  M. Nishida,et al.  Purinergic P2Y receptors: Molecular diversity and implications for treatment of cardiovascular diseases , 2017, Pharmacology & therapeutics.

[2]  K. Guan,et al.  PDE2 at the crossway between cAMP and cGMP signalling in the heart. , 2017, Cellular signalling.

[3]  A. Kamkin,et al.  Diadenosine pentaphosphate affects electrical activity in guinea pig atrium via activation of potassium acetylcholine-dependent inward rectifier , 2017, The Journal of Physiological Sciences.

[4]  D. Abramochkin,et al.  The role of diadenosine pentaphosphate and nicotinamide adenine dinucleotide (NAD+) as potential nucleotide comediators in the adrenergic regulation of cardiac function , 2017, Neurochemical Journal.

[5]  D. Abramochkin,et al.  Effects of Nicotinamide Adenine Dinucleotide (NAD+) and Diadenosine Tetraphosphate (Ap4A) on Electrical Activity of Working and Pacemaker Atrial Myocardium in Guinea Pigs , 2016, Bulletin of Experimental Biology and Medicine.

[6]  J. Pérez-Schindler,et al.  Single inhibition of either PDE3 or PDE4 unmasks β2-adrenoceptor-mediated inotropic and lusitropic effects in the left but not right ventricular myocardium of rat. , 2015, European journal of pharmacology.

[7]  L. Durnin,et al.  The purinergic neurotransmitter revisited: a single substance or multiple players? , 2014, Pharmacology & therapeutics.

[8]  J. Jankowski,et al.  Highly sensitive, selective and rapid LC-MS method for simultaneous quantification of diadenosine polyphosphates in human plasma. , 2014, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[9]  D. Cooper,et al.  AKAP79, PKC, PKA and PDE4 participate in a Gq-linked muscarinic receptor and adenylate cyclase 2 cAMP signalling complex. , 2013, The Biochemical journal.

[10]  W. Knight,et al.  Therapeutic potential of PDE modulation in treating heart disease. , 2013, Future medicinal chemistry.

[11]  L. Monge,et al.  Coronary response to diadenosine tetraphosphate after ischemia-reperfusion in the isolated rat heart. , 2011, European journal of pharmacology.

[12]  M. Conti,et al.  Conserved expression and functions of PDE4 in rodent and human heart , 2010, Basic Research in Cardiology.

[13]  Clint L. Miller,et al.  Targeting Cyclic Nucleotide Phosphodiesterase in the Heart: Therapeutic Implications , 2010, Journal of cardiovascular translational research.

[14]  H. Mischak,et al.  Dinucleoside polyphosphates: strong endogenous agonists of the purinergic system , 2009, British journal of pharmacology.

[15]  I. Hers,et al.  Protein Kinase C-mediated Phosphorylation and Activation of PDE3A Regulate cAMP Levels in Human Platelets* , 2009, Journal of Biological Chemistry.

[16]  G. Burnstock,et al.  P2 receptors in cardiovascular regulation and disease , 2008, Purinergic Signalling.

[17]  Eric A. Barnard,et al.  International Union of Pharmacology LVIII: Update on the P2Y G Protein-Coupled Nucleotide Receptors: From Molecular Mechanisms and Pathophysiology to Therapy , 2006, Pharmacological Reviews.

[18]  G. Reiser,et al.  Diadenosine and diuridine poly(borano)phosphate analogues: synthesis, chemical and enzymatic stability, and activity at P2Y1 and P2Y2 receptors. , 2006, Journal of medicinal chemistry.

[19]  H. Schlüter,et al.  Uridine adenosine tetraphosphate: a novel endothelium- derived vasoconstrictive factor , 2005, Nature Medicine.

[20]  J. Pintor,et al.  Interaction between Dinucleotide and Nicotinic Receptors in Individual Cholinergic Terminals , 2004, Journal of Pharmacology and Experimental Therapeutics.

[21]  E. Jacobs,et al.  P2Y purine receptor responses and expression in the pulmonary circulation of juvenile rabbits. , 2004, American journal of physiology. Heart and circulatory physiology.

[22]  H. Schlüter,et al.  Identification and Quantification of Diadenosine Polyphosphate Concentrations in Human Plasma , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[23]  J. Pintor,et al.  Ca2+ Signalling in Brain Synaptosomes Activated by Dinucleotides , 2003, The Journal of Membrane Biology.

[24]  Hong Wang,et al.  P2Y receptor specific for diadenosine tetraphosphate in lung: selective inhibition by suramin, PPADS, Ip5I, and not by MRS-2197. , 2003, European journal of pharmacology.

[25]  S. Buvinic,et al.  P2Y1 and P2Y2 receptors are coupled to the NO/cGMP pathway to vasodilate the rat arterial mesenteric bed , 2002, British journal of pharmacology.

[26]  M. LeWinter,et al.  Activation of PKC decreases myocardial O2 consumption and increases contractile efficiency in rats. , 2001, American journal of physiology. Heart and circulatory physiology.

[27]  D. Sheridan,et al.  Contribution of nitric oxide and prostanoids to the cardiac electrophysiological and coronary vasomotor effects of diadenosine polyphosphates. , 2001, The Journal of pharmacology and experimental therapeutics.

[28]  G. Vassort.  Adenosine 5'-triphosphate: a P2-purinergic agonist in the myocardium. , 2001, Physiological reviews.

[29]  R. Gerzer,et al.  NO-independent regulatory site on soluble guanylate cyclase , 2001, Nature.

[30]  Q. Shan,et al.  Cardiac and vascular effects of nitric oxide synthase inhibition in lipopolysaccharide-treated rats. , 2000, European journal of pharmacology.

[31]  K. Rahn,et al.  Diadenosine polyphosphates cause contraction and relaxation in isolated rat resistance arteries. , 2000, The Journal of pharmacology and experimental therapeutics.

[32]  J. Pei,et al.  The role of phosphodiesterase in mediating the effect of protein kinase C on cyclic AMP accumulation upon kappa-opioid receptor stimulation in the rat heart. , 2000, The Journal of pharmacology and experimental therapeutics.

[33]  H. Schlüter,et al.  Identification and characterization of diadenosine 5′,5‴‐P1,P2‐diphosphate and diadenosine 5′,5‴‐P1,P3‐triphosphate in human myocardial tissue , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  D. Sheridan,et al.  The effects of diadenosine polyphosphates on the cardiovascular system. , 1999, Cardiovascular research.

[35]  S. Huke,et al.  Inotropic effects of diadenosine tetraphosphate (AP4A) in human and animal cardiac preparations. , 1999, The Journal of pharmacology and experimental therapeutics.

[36]  J. Pintor,et al.  The neurotransmitter role of diadenosine polyphosphates , 1998, FEBS letters.

[37]  J. Nishimura,et al.  Diadenosine polyphosphates directly relax porcine coronary arterial smooth muscle. , 1997, The Journal of pharmacology and experimental therapeutics.

[38]  E. Barnard,et al.  Molecular biology of P2Y purinoceptors: expression in rat heart. , 1996, Journal of autonomic pharmacology.

[39]  G. Burnstock,et al.  The activation of P1‐ and P2‐purinoceptors in the guinea‐pig left atrium by diadenosine polyphosphates , 1996, British journal of pharmacology.

[40]  W. Paulus,et al.  Myocardial contractile response to nitric oxide and cGMP. , 1996, Circulation.

[41]  H. Schlüter,et al.  Diadenosine phosphates and the physiological control of blood pressure , 1994, Nature.

[42]  M. Miras-Portugal,et al.  Diadenosine polyphosphate (ApxA) as new neurotransmitters , 1993 .

[43]  R. Busse,et al.  Potent effects of AP3A and AP4A on coronary resistance and autacoid release of intact rabbit hearts. , 1991, The American journal of physiology.

[44]  G. Isenberg,et al.  Calcium tolerant ventricular myocytes prepared by preincubation in a “KB medium” , 1982, Pflügers Archiv.

[45]  H. Nechushtan,et al.  Amino-acyl tRNA synthetases generate dinucleotide polyphosphates as second messengers: functional implications. , 2014, Topics in current chemistry.

[46]  G. Reiser,et al.  Hetero-oligomerization of the P2Y11 receptor with the P2Y1 receptor controls the internalization and ligand selectivity of the P2Y11 receptor. , 2008, The Biochemical journal.

[47]  G. Reiser,et al.  Hetero-oligomerization of the P2Y11 receptor with the P2Y1 receptor controls the internalization and ligand selectivity of the P2Y11 receptor. , 2008, The Biochemical journal.

[48]  H. Schlüter,et al.  Inotropic effects of diadenosine tetraphosphate in isolated canine cardiac preparations. , 1999, Journal of cardiovascular pharmacology.

[49]  W. Thompson.  Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function. , 1991, Pharmacology & therapeutics.